Cytokines, such as interleukin (IL)-23, are key drivers of intestinal inflammation in patients with inflammatory bowel disease. While all IL-23 targeted agents neutralize IL-23, differences in antibody structure can improve the ability of these agents to capture this inflammatory cytokine from a main source of production, namely CD64-positive myelocytes. As the treatment landscape of IL-23 targeted therapies continues to expand, it is crucial that gastroenterology clinicians understand the differentiating aspects of current and emerging treatments in order to develop an efficacious, lasting, and individualized treatment plan for each patient. In this CME Outfitters recorded symposium, expert faculty will review the functions of Fc gamma receptors, CD64 and its connection with IL-23, the molecular attributes of anti IL-23 therapies, in vivo data on expression of CD64 monocytes, and the most recent clinical trial data differentiating the anti IL-23 agents. To demonstrate these concepts, animated 3-D models will be included in the educational program and available to attendees.
- Provider:CME Outfitters, LLC
- Activity Link: https://www.cmeoutfitters.com/activity/whats-il-23-got-to-do-with-it-targeted-therapies-in-the-management-of-ibd-2/
- Start Date: 2024-11-04 06:00:00
- End Date: 2024-11-04 06:00:00
- Credit Details: IPCE Credits: 1.5 hours
AAPA Category 1 Credit™️: 1.5 hours
AMA PRA Category 1 Credit™️: 1.5 hours
Nursing: 1.5 hours - MOC Credit Details: ABIM - 1.5 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Janssen (Any division) - Amount: 0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Gastroenterology, Internal Medicine